Inotiv Inc., a pharmaceutical development firm, recently announced plans to expand in St. Louis, Missouri. The company plans to bolster its presence in the region, purchasing its existing facility in Maryland Heights and expanding its footprint by 20,000 sq. ft. to add more laboratory and office space.
“Expansion of our operations is part of a strategic investment campaign we initiated at the beginning of 2020 to broaden our laboratory-based solutions and services,” said Robert Leasure Jr., Inotiv’s President and CEO. “The expansion will also offer additional space for continued growth and opportunities from the Bolder BioPATH, Inc. and HistoTox Labs, Inc. acquisitions. Investments to date have also included upgrading our technology in mass spectrometry, automation, and flow cytometry technology, as well as recruiting high-level scientific leadership — all of which we believe will directly benefit our clients in their ultimate goal of delivering traditional therapeutics and novel biotherapies to patients.”
Inotiv is a contract research organization that provides drug discovery and development services. Its St. Louis site provides pharmacology, toxicology, drug metabolism and pharmacokinetics (DMPK), histology, pathology and cell and molecular biology services.
“The planned strategic expansion of our DMPK, cell & molecular biology, and investigative pathology laboratory footprint will extend Inotiv’s reach into earlier stages of drug discovery, ultimately increasing engagement of our pharmacology and toxicology operations and histopathology services,” said Stewart Jacobson, Vice President of Pathology and St. Louis Site Leader at Inotiv.